文献速递淋巴瘤

制备过程中一致的体外细胞增殖可预测CAR-T细胞治疗后良好结局

Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post-CAR-T-cell therapy.
PubMed 文献 · Br J Haematol · 2025-07-09

该研究分析75例接受替沙来仑赛治疗的弥漫大B细胞淋巴瘤患者,将临床记录与制备参数合并。21例(28%)制备期间细胞数下降定义为生长不良;生长良好组总缓解率显著更高(85.2% vs. 52.4%;p=0.006),多因素分析显示无进展生存期和总生存期显著更优。

要点

  • 制备期间细胞数下降(生长不良)见于21/75例(28%)。
  • 生长良好组总缓解率85.2% vs. 生长不良组52.4%(p=0.006)。
  • 生长良好组无进展生存期aHR 0.377(95%CI 0.180-0.789;p=0.010)。

核心结论

  • 制备期间细胞生长良好可预测CAR-T治疗后良好结局。
  • 识别影响制备参数的临床因素可能改善CAR-T治疗后结局。

研究设计与样本

  • 分析75例接受替沙来仑赛治疗的弥漫大B细胞淋巴瘤患者,将临床记录与制备参数合并。

主要发现

  • 75例中21例(28%)制备期间细胞数下降,定义为生长不良。
  • 生长良好组总缓解率85.2% vs. 生长不良组52.4%(p=0.006),且输注后外周血淋巴细胞增高更明显。
  • 多因素分析:生长良好组无进展生存期aHR 0.377(95%CI 0.180-0.789;p=0.010),总生存期aHR 0.191(95%CI 0.071-0.510;p=0.001),疾病进展累积发生率aHR 0.412(95%CI 0.198-0.858;p=0.018),均优于生长不良组,校正临床因素、采集至输注间桥接治疗及输注时疾病状态后仍显著。

关键数值与推荐

  • 生长不良定义为制备期间细胞数任何下降。
  • 总缓解率:生长良好组85.2% vs. 生长不良组52.4%(p=0.006)。
  • 无进展生存期aHR 0.377(95%CI 0.180-0.789;p=0.010)。
  • 总生存期aHR 0.191(95%CI 0.071-0.510;p=0.001)。
  • 疾病进展累积发生率aHR 0.412(95%CI 0.198-0.858;p=0.018)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Efficacy of chimeric antigen receptor (CAR) T-cell therapy hinges on CAR-T potency, as well as on tumour traits and disease status. Potency assessment currently relies on post-infusion in vivo growth; therefore, manufacturing metrics could provide early potency predictions, enabling potency-guided strategies. To assess the impact of ex vivo cell growth during manufacturing on clinical outcomes, we analysed diffuse large B-cell lymphoma patients treated with tisagenlecleucel, merging clinical records with manufacturing parameters. Of 75 cases, 21 (28%) showed poor growth, indicated by any decrease in cell number during manufacturing. Good growth correlated with significantly better overall response rate (85.2% vs. 52.4%; p = 0.006), with enhanced lymphocyte increase in peripheral blood after infusion. Multivariate analysis revealed that this group had significantly higher progression-free survival (PFS) (adjusted hazard ratio [aHR]: 0.377; 95% confidence interval [CI]: 0.180-0.789; p = 0.010) and overall survival (OS) (aHR: 0.191; 95% CI: 0.071-0.510; p = 0.001), with lower cumulative incidence of disease progression (aHR: 0.412; 95% CI: 0.198-0.858; p = 0.018), compared to the poor growth group, even after adjusting for clinical factors, bridging therapies performed between apheresis and infusion and disease status at infusion. Our findings suggest that good cell growth during manufacturing predicts favourable post-CAR-T outcomes. Identifying clinical factors that influence manufacturing parameters could improve post-CAR-T outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Jo T, Arai Y, Shimizu T, et al. Consistent ex vivo cell proliferation during manufacturing predicts favourable outcomes post-CAR-T-cell therapy. Br J Haematol. 2025. PMID: 40633933. doi:10.1111/bjh.20266

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。